molecules-logo

Journal Browser

Journal Browser

Special Issue "Transcription Factors: Role in Degenerative Diseases"

A special issue of Molecules (ISSN 1420-3049).

Deadline for manuscript submissions: closed (30 December 2019).

Special Issue Editor

Dr. Maria Teresa Valenti
Website
Guest Editor
Department of Medicine, Internal Medicine Section, Verona, Italy
Interests: trascription factors, stem cells, bone, cancer, degenerative diseases
Special Issues and Collections in MDPI journals

Special Issue Information

Dear Colleagues,

Degenerative diseases are serious pathological conditions with critical social outcomes. In fact, neurodegenerative diseases as well as bone and musculoskeletal disorders, cardiovascular diseases, diabetes, and cancer affect a large part of the population. Unfortunately, therapeutic approaches are not able to counteract these degenerative diseases. In fact, molecular and cellular defects causing degeneration are not completely understood and specific therapeutic targets are lacking. Among the molecules involved in degenerative diseases, transcription factors play an important role in this context.  Transcription factors, by acting on gene expression, can affects cellular processes and, thereby, can induce cellular injury, leading to degenerative diseases. However, transcription factors have been ignored by the pharmaceutical industry as drug design against them has proven difficult. The possibility to identify targeted drugs with higher affinity and specificity is an important goal to prevent degenerative diseases.

In this Special Issue of Molecules, we will address the role of transcription factors in inducing cellular alterations in different degenerative diseases. Papers describing pharmaceutical approaches in this context are welcome too.

We encourage researchers to contribute experimental papers, reports, or review articles.

Dr. Maria Teresa Valenti
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Trascription factors
  • Gene expression
  • Degenerative diseases
  • Stem cells

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Open AccessArticle
BEL β-Trefoil Reduces the Migration Ability of RUNX2 Expressing Melanoma Cells in Xenotransplanted Zebrafish
Molecules 2020, 25(6), 1270; https://doi.org/10.3390/molecules25061270 - 11 Mar 2020
Cited by 1
Abstract
RUNX2, a master osteogenic transcript ion factor, is overexpressed in several cancer cells; in melanoma it promotes cells migration and invasion as well as neoangiogenesis. The annual mortality rates related to metastatic melanoma are high and novel agents are needed to improve melanoma [...] Read more.
RUNX2, a master osteogenic transcript ion factor, is overexpressed in several cancer cells; in melanoma it promotes cells migration and invasion as well as neoangiogenesis. The annual mortality rates related to metastatic melanoma are high and novel agents are needed to improve melanoma patients’ survival. It has been shown that lectins specifically target malignant cells since they present the Thomsen–Friedenreich antigen. This disaccharide is hidden in normal cells, while it allows selective lectins binding in transformed cells. Recently, an edible lectin named BEL β-trefoil has been obtained from the wild mushroom Boletus edulis. Our previous study showed BEL β-trefoil effects on transcription factor RUNX2 downregulation as well as on the migration ability in melanoma cells treated in vitro. Therefore, to better understand the role of this lectin, we investigated the BEL β-trefoil effects in a zebrafish in vivo model, transplanted with human melanoma cells expressing RUNX2. Our data showed that BEL β-trefoil is able to spread in the tissues and to reduce the formation of metastases in melanoma xenotransplanted zebrafish. In conclusion, BEL β-trefoil can be considered an effective biomolecule to counteract melanoma disease. Full article
(This article belongs to the Special Issue Transcription Factors: Role in Degenerative Diseases)
Show Figures

Figure 1

Back to TopTop